Ligand Pharmaceuticals Inc.

LGND Nasdaq SEC CIK 886163
Follow Ligand Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $78.7M −31.8% vs same quarter last year
Net income −$28.5M −124.3% vs same quarter last year
EPS, diluted −$1.43 −125.2% vs same quarter last year
Operating cash flow −$27.6M −310.8% vs same quarter last year
Revenue by quarter
$42.8M
$45.3M
$47.6M
$115.5M
$59.7M
$51.7M
$63.7M
$78.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400M$600M$800MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$268.1M$124.5M
FY24$167.1M−$4M
FY23$131.3M$52.2M
FY22$196.2M−$33.4M
FY21$241.5M$57.1M
FY20$163.6M−$3M
FY19$120.3M$629.3M
FY18$251.5M$143.3M
FY17$141.1M$12.6M
FY16$109M−$1.6M
FY15$71.9M$229.8M
FY14$64.5M$12M
FY13$49M$11.4M
FY12$31.4M−$527K
FY11$30M$9.7M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−200%0%200%400%600%800%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25-15.3%46.4%
FY24-−13.5%−2.4%
FY23-9.1%39.7%
FY22-1.5%−17%
FY21-43%23.7%
FY20-22.9%−1.8%
FY19-671%523.2%
FY1897.5%65.1%57%
FY1796.2%48.2%8.9%
FY1694.9%40.3%−1.5%
FY1591.9%38%319.6%
FY1485.8%30.4%18.6%
FY1388.3%30.5%23.3%
FY1288.5%0.6%−1.7%
FY1183.7%−2.9%32.3%
Free cash flowOperating cash flow minus capital expenditure
−$100M$0$100M$200MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$48.9M
FY24$95.2M
FY23$46.1M
FY22$119.9M
FY21$70M
FY20$50.1M
FY19−$31.9M
FY18$193.2M
FY17$86.4M
FY16$58.9M
FY15$41.6M
FY14$20.6M
FY13$20.3M
FY12−$434K
FY11−$1.3M
Returned to shareholdersDividends paid and shares bought back
$0$200M$400M$600MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25$15M
FY24$0
FY23$0
FY22$0
FY21$0
FY20$78M
FY19$453M
FY18$122.9M
FY17$2M
FY16$3.9M
FY15$489K
FY14$68M
FY13$0
FY12$0
FY11$55K
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Ligand Pharmaceuticals
  • Healthcare median
−200%0%200%400%600%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearLigand PharmaceuticalsHealthcare median
FY2546.4%−30.6%
FY24−2.4%−47%
FY2339.7%−58%
FY22−17%−80.4%
FY2123.7%−71.8%
FY20−1.8%−62.2%
FY19523.2%−46.2%
FY1857%−49.6%
FY178.9%−45.9%
FY16−1.5%−36%
FY15319.6%−37.8%
FY1418.6%−35.5%
FY1323.3%−37.1%
FY12−1.7%−29.1%
FY1132.3%−27.9%